Herrera-Porro JA, Castro-Cárdenas K, Iserm-Pérez BE

Language: Spanish
References: 25
Page: 1-16
PDF size: 844.16 Kb.

ABSTRACT

Introduction: periocular squamous cell carcinoma is a malignant tumor of the keratinizing cells of the epidermis and its annexes. Therapeutics focuses on its elimination without functional and aesthetic sequelae. HeberFERON® –currently in phase IV clinical trial– is a drug that, due to its synergistic antiproliferative effect, is a valid option to treat this tumor.
Objective: to present a series of three patients diagnosed with periocular squamous cell carcinoma in whom the treatment was effective.
Case presentation: three patients were treated with HeberFERON®. The first two presented squamous cell carcinomas on the periocular surface: one conjunctival-corneal and one tarsoconjunctival; in both, the medicine was used by the intramuscular and intralesional routes. The third patient had a cutaneous squamous cell carcinoma of the upper eyelid, treated with intralesional injection. In the first two the tumors were considerably reduced, but total resolution was achieved with minimally invasive surgical interventions. In the third, the tumor was also reduced and with the use of cryotherapy the operation was avoided.
Conclusions: treatment with HeberFERON® of periocular squamous cell carcinomas was effective in all three patients.

REFERENCES

1. Sotoca-Momblona JM. Cuarenta Años de inteferones. Farm Hosp [Internet]. 1999 [citado 27 Jul 2017];23(4):205-13. Disponible en: https://www.researchgate.net/profile/Jm-Momblona/publication/242133342_CUARENTA_ANOS_DE_INTERFERONES/links/566aab7708ae62b05f033d56/CUARENTA-ANOS-DE-INTERFERONES.pdf

2. González-Sánchez N, Armada-Esmores Z, Llópiz-Casanova L. Propiedades de los interferones y su acción antitumoral. Medicent Electrón [Internet]. Sep 2017 [citado 22 Ene 2018];21(3):192-8. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1029-30432017000300002&script=sci_arttext&tlng=en

3. Kontsek P, Kontseková E. Forty years of interferon. Acta Virol [Internet]. Dic 1997 [citado 27 Jul 2017];41(6):349-53. Disponible en: http://www.aepress.sk/acta/full/av697j.pdf

4. Bello-Álvarez C, Vázquez-Blomquist D, Miranda J, García Y, Novoa LI, Palenzuela D, et al. Regulation by IFN-α/IFN-γ co-formulation (HerberPAG®) of genes involved in interferon-STAT-pathways and apoptosis in U87MG. Curr Top Med Chem [Internet]. 2014 [citado 10 Ene 2015];14(3):351-8. Disponible en: https://www.researchgate.net/profile/Dania-Vazquez-Blomquist/publication/259199696_Regulation_by_IFN-aIFN-g_co-formulation_HerberPAGR_of_genes_involved_in_interferon-STAT-pathways_and_apoptosis_in_U87MG/links/5637d32508ae7f7eb1852c8d/Regulation-by-IFN-a-IFN-g-co-formulation-HerberPAGR-of-genes-involved-in-interferon-STAT-pathways-and-apoptosis-in-U87MG.pdf

5. Mercadillo-Pérez P, Moreno-López LM. Fisiopatología del carcinoma epidermoide. Dermatol Rev Mex. 2013;57:118-127.

6. Bowling B. Kanski Oftalmología Clínica. 8va. ed. Barcelona: Elsevier; 2016.

7. Paul S, Ribback S, Tost F. Recognised occupational disease and squamous cell carcinoma in periocular region. Klin Montbl Augenheilkd [Internet]. Ene 2019 [citado 1 Ago 2019];236(01):47-9. Disponible en: https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0749-8994.pdf

8. Silverman N, Shinder R. What's New in eyelid tumors. Asia Pac J Ophthalmol (Phila) [Internet]. Abr 2017 [citado 27 Jul 2017];6(2):143-52. Disponible en: https://journals.lww.com/apjoo/Fulltext/2017/03000/What_s_New_in_Eyelid_Tumors.5.aspx

9. Damasceno JC, Isenberg J, Lopes LR, Hime B, Fernandes BF, Lowen M, et al. Largest case series of Latin American eyelid tumors over 13-years from a single center in Sao Paulo, Brazil. Arq Bras Oftalmol [Internet]. Feb 2018 [citado 1 Ago 2019];81(1):7-11. Disponible en: https://www.scielo.br/j/abo/a/tVvgKTkGmc93RjNPj8RWFFr/?format=pdf&lang=en

10. Capiz-Correa DR, García-Córdoba T, Tejeda-Rojas GM, Lozano-Alcázar J, Pérez-Cano HJ. Características del carcinoma epidermoide de conjuntiva en un hospital de concentración oftalmológico en México. Rev Mex Oftalmol [Internet]. Jun 2017 [citado 27 Jul 2017];91(3):142-7. Disponible en: https://www.sciencedirect.com/science/article/pii/S0187451916300373/pdfft?md5=c57f5678c88ae9c3a9fcaba85a757b2e&pid=1-s2.0-S0187451916300373-main.pdf

11. Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, Shields JA. Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes--the 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol (Phila) [Internet]. Abr 2017 [citado 27 Jul 2017];6(2):109-20. Disponible en: https://www.researchgate.net/profile/Kareem-Sioufi/publication/314144030_Conjunctival_TumorsReview_of_Clinical_Features_Risks_Biomarkers_and_Outcomes/links/58f7cd0baca272c34c380a9f/Conjunctival-TumorsReview-of-Clinical-Features-Risks-Biomarkers-and-Outcomes.pdf

12. Ruiz-Galindo E, Durán-Padilla MA, Muñoz-Gutiérrez G. Detección del virus del papiloma humano en la neoplasia escamosa de la superficie ocular por histopatología y estudio molecular. Salud(i)Ciencia [Internet]. Mar 2014 [citado 27 Jul 2017];20(4):351-6. Disponible en: https://www.siicsalud.com/saludiciencia/pdf/sic_20_4_32814.pdf#page=9

13. Vijaya-Pai H, Handa D, Padma-Priya J. Primary squamous cell carcinoma arising from palpebral conjunctiva: A rare presentation. Indian J Ophthalmol [Internet]. Feb 2018 [citado 1 Ago 2019];66(2):304-6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819124/pdf/IJO-66-304.pdf

14. Gichuhi S, Sagoo MS. Squamous cell carcinoma of the conjunctiva. Community Eye Health [Internet]. 2016 [citado 25 Ago 2017];29(95):52-3. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340104/pdf/jceh_29_95_052.pdf

15. Castañeda-Morales A. Frecuencia de neoplasia escamosa de la superficie ocular coexistente con pterigio [Internet]. Bogotá: Universidad del Rosario; 2015 [citado 5 Oct 2019]. Disponible en: http://repository.urosario.edu.co/bitstream/handle/10336/11831/CastanedaMorales-Alexander-2015.pdf?sequence=1&isAllowed=y

16. Echchaoui A, Benyachou M, Houssa A, Kajout M, Oufkir AA, Hajji C, et al. Management of eyelid carcinomas: retrospective bicentric study of 64 cases and review of the literature. J Fr Ophtalmol [Internet]. Feb 2016;39(2):187-94. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26826743/

17. Hanlon A, Kim J, Leffell DJ. Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face. J Am Acad Dermatol [Internet]. Dec 2013 [citado 22 Ene 2017];69(6):1070-2. Disponible en: https://www.jaad.org/action/showPdf?pii=S0190-9622%2813%2900763-9

18. Clifford JL, Yang X, Walch E, Wang M, Lippman SM. Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. Mol Cancer Ther [Internet]. May 2003 [citado 22 Ene 2017];2(5):453-9. Disponible en: https://mct.aacrjournals.org/content/2/5/453.full-text.pdf

19. Yamada S, Jinnin M, Kajihara I, Nakashima T, Aoi J, Harada M, et al. Cytokine expression profiles in the sera of cutaneous squamous cell carcinoma patients. Drug Discov Ther [Internet]. 2016 [citado 22 Ene 2017];10(3):172-6. Disponible en https://www.jstage.jst.go.jp/article/ddt/10/3/10_2016.01032/_pdf/-char/en

20. Kusumesh R, Ambastha A, Sinha B, Kumar R. Topical Interferon α-2b as a single therapy for primary ocular Surface squamous neoplasia. Asia Pac J Ophthalmol (Phila). Oct 2015;4(5):279-82. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26176194/

21. Bello-Rivero I, García-Vega Y, Valenzuela-Silva C, Bello-Álvarez C, Vázquez-Blomquist D, López-Saura P, et al. Development of a new formulation of interferons (HEBERPAG) for BCC treatment, J Cancer Res Ther [Internet]. 2013 [citado 11 Abr 2015];1(10):235-43. Disponible en: https://pdfs.semanticscholar.org/f5b7/df2d1d0d8499f9417bc9af811f5a185d8323.pdf

22. Bello-Rivero I. A synergistic immunotherapy for skin cancer [Internet]. Lima: Scientia; 2016 [citado 12 Oct 2017]. Disponible en: https://www.scientia.global/wp-content/uploads/2016/08/Iraldo-Bello-Rivero.pdf

23. Anasagasti-Angulo L, García-Vega Y, Barcelona-Pérez S, López-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. BMC Cancer [Internet]. 2009 [citado 12 Oct 2017].9:262. Disponible en: https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-9-262.pdf

24. García-Vega Y, Anasagasti-Angulo L, Valenzuela-Silva C, Navarro-Mestre M, Maribeth-Ordóñez S, Acosta-Medina D, et al. Retrospective study of periocular non melanoma skin cancer treated with the combination of IFN alpha 2b and gamma (HeberPAG). J Clin Exp Ophthalmol [Internet]. 2015 [citado 11 br 2015];6(5):1000478. Disponible en: https://www.researchgate.net/profile/Yanelda-Garcia/publication/284208975_Retrospective_Study_of_Periocular_Non_Melanoma_Skin_Cancer_Treated_with_the_Combination_of_IFN_alpha2b_and_Gamma_HeberPAG/links/5a58c4130f7e9b5fb383f098/Retrospective-Study-of-Periocular-Non-Melanoma-Skin-Cancer-Treated-with-the-Combination-of-IFN-alpha2b-and-Gamma-HeberPAG.pdf

25. Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia. Am J Ophthalmol [Internet]. Mar 2019 [citado 1 Ago 2019];199:216-22. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382615/pdf/nihms-1513224.pdf